Johnson & Johnson's Q2 2015 earnings call showed strong operational performance, especially in the consumer segment, which grew by 3.1% and maintained market share.  The pharmaceuticals segment was impacted by competition in the hepatitis C market, but key products like INVOKANA and XARELTO continued to show strong growth.  Management reiterated a commitment to innovation and strategic investments in R&D and technology integration, positioning the company for continued growth despite short-term pressures.
[1]
